A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Examining the shift from fast answers to verified intelligence in enterprise AI.
Updated
January 8, 2026 6:33 PM
Startup employee reviewing business metrics on an AI-powered dashboard. PHOTO: FREEPIK
Neuron7.ai, a company that builds AI systems to help service teams resolve technical issues faster, has launched Neuro. It is a new kind of AI agent built for environments where accuracy matters more than speed. From manufacturing floors to hospital equipment rooms, Neuro is designed for situations where a wrong answer can halt operations.
What sets Neuro apart is its focus on reliability. Instead of relying solely on large language models that often produce confident but inaccurate responses, Neuro combines deterministic AI — which draws on verified, trusted data — with autonomous reasoning for more complex cases. This hybrid design helps the system provide context-aware resolutions without inventing answers or “hallucinating”, a common issue that has made many enterprises cautious about adopting agentic AI.
“Enterprise adoption of agentic AI has stalled despite massive vendor investment. Gartner predicts 40% of projects will be canceled by 2027 due to reliability concerns”, said Niken Patel, CEO and Co-Founder of Neuron7. “The root cause is hallucinations. In service operations, outcomes are binary. An issue is either resolved or it is not. Probabilistic AI that is right only 70% of the time fails 30% of your customers and that failure rate is unacceptable for mission-critical service”.
That concern shaped how Neuro was built. “We use deterministic guided fixes for known issues. No guessing, no hallucinations — and reserve autonomous AI reasoning for complex scenarios. What sets Neuro apart is knowing which mode to use. While competitors race to make agents more autonomous, we're focused on making service resolution more accurate and trusted”, Patel explained.
At the heart of Neuro is the Smart Resolution Hub, Neuron7’s central intelligence layer that consolidates service data, knowledge bases and troubleshooting workflows into one conversational experience. This means a technician can describe a problem — say, a diagnostic error in an MRI scanner — and Neuro can instantly generate a verified, step-by-step solution. If the problem hasn’t been encountered before, it can autonomously scan through thousands of internal and external data points to identify the most likely fix, all while maintaining traceability and compliance.
Neuro’s architecture also makes it practical for real-world use. It integrates seamlessly with enterprise systems such as Salesforce, Microsoft, ServiceNow and SAP, allowing companies to embed it within their existing support operations. Early users of Neuron7’s platform have reported measurable improvements — faster resolutions, higher customer satisfaction and reduced downtime — thanks to guided intelligence that scales expert-level problem solving across teams.
The timing of Neuro’s debut feels deliberate. As organizations look to move past the hype of generative AI, trust and accountability have become the new benchmarks. AI systems that can explain their reasoning and stay within verifiable boundaries are emerging as the next phase of enterprise adoption.
“The market has figured out how to build autonomous agents”, Patel said. “The unsolved problem is building accurate agents for contexts where errors have consequences. Neuro fills that gap”.
Neuron7 is building a system that knows its limits — one that reasons carefully, acts responsibly and earns trust where it matters most. In a space dominated by speculation, that discipline may well redefine what “intelligent” really means in enterprise AI.